ArticleNPJ precision oncology2026
Comparison of gene fusion detection algorithms reveals frequently overlooked driver fusions in hematologic malignancies.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Accurate detection of driver gene fusions is essential for the diagnosis, treatment, and prognostic prediction of hematologic malignancies. Despite increasing reliance on RNA sequencing (RNA-seq) for fusion detection, its algorithms have not been sufficiently examined for their ability to detect clinically relevant driver fusions. We evaluated 12 algorithms using conventional RNA-seq from 170 cell lines and targeted RNA-seq from 26 cell lines and 165 clinical samples. The true positive rate, based on 61 and 24 driver fusion-cell line pairs for conventional and targeted RNA-seq, varied between 0.41-1 (median 0.81) and 0-1 (median 0.85), respectively. Many algorithms failed to detect fusions resulting from small deletions (including STIL::TAL1 and FIP1L1::PDGFRA), lowly expressed fusions, and IGH fusions (DUX4::IGH and IGH::NSD2). Targeted RNA-seq more sensitively detected driver fusions than conventional RNA-seq, especially lowly expressed ones. One algorithm, Arriba, detected all driver fusions. These findings will inform algorithm selection in clinical settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.